Experimental COVID-19 vaccine safe, generates immune response

(NIH/National Institute of Allergy and Infectious Diseases) An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes COVID-19, was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published today in The New England Journal of Medicine. The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID). The experimental vaccine is being co-develo...